Betahistine - Intas Pharmaceuticals
Alternative Names: Betahistine DiHCL; Betahistine dihydrochloride - Intas PharmaceuticalsLatest Information Update: 06 Oct 2022
At a glance
- Originator Intas Pharmaceuticals
- Class Amines; Anti-inflammatories; Antidementias; Pyridines; Small molecules; Vestibular disorder therapies
- Mechanism of Action Histamine H1 receptor agonists; Histamine H3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Meniere's disease
Most Recent Events
- 28 Dec 2021 Phase-III clinical trials in Meniere's disease (In adults) in France (PO) (EudraCT2020-005246-42)
- 28 Dec 2021 Phase-III clinical trials in Meniere's disease (In adults) in Spain (PO) (EudraCT2020-005246-42)